US demand for drug delivery systems will grow 10 percent annually through 2012. Oral types will remain the largest drug delivery category while parenteral, inhalation and implantable systems grow the fastest. Parenteral formulations will eventually surpass oral dosages as the largest product group.
This study analyzes the $80.2 billion US drug delivery system industry. It presents historical demand data for the years 1997, 2002 and 2007, and forecasts for 2012 and 2017 by material (e.g., sterile and purified water, synthetic polymers, cellulose derivatives, minerals); type (e.g., oral, parenteral, inhalation, transdermal, implantable); and application.
The study also considers market environment factors, details industry structure, evaluates company market share and profiles 30 leading industry players, including GlaxoSmithKline, Genentech, AstraZeneca, Abbott Laboratories, Wyeth, Eli Lilly, Johnson & Johnson, Sanofi-Aventis, Amgen, and Pfizer.
